Johnson & Johnson (J&J) has announced that it has completed the $1.25bn acquisition of Yellow Jersey Therapeutics.
Through the all-cash purchase, J&J is set to gain ownership of NM26, a novel bispecific antibody under development for the treatment of atopic dermatitis. The antibody is designed to inhibit the interleukin (IL)-4R and IL-31 cytokine pathways, thereby mediating and stabilising inflammatory response. The candidate is currently in a Phase I study (NCT05859724) evaluating single and multiple doses of the treatment.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
“NM26 is designed to help different subpopulations of patients by targeting two disease-driving pathways, which is key when treating a heterogeneous disease like AD,” said David Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson Innovative Medicine in the 11 July press release.
Atopic dermatitis is a chronic inflammatory skin disorder that results in a damaged, itchy, and irritated skin barrier. As per J&J Worldwide Vice President, Immunology at Johnson & Johnson, Candice Long, the unmet need is high as the existing treatment landscape means that nearly three-quarters of patients with atopic dermatitis do not achieve remission.
NM26 was developed using Numab Therapeutics’ proprietary Multispecific Antibody-based Therapeutics by Cognate Heterodimerization (MATCH) technology, which is designed to develop highly potent and stable antibody Fv fragments. Yellow Jersey is a demerged spin-off of Numab that holds the rights to the NM26 program.
As per the initial acquisition announcement on 28 May, J&J will enter a separate agreement to secure rights to NM26 in the Asia Pacific region, as Numab had previously licensed rights to the treatment to Japan-based Kaken Pharmaceutical.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn a bid to secure its position as a dermatology powerhouse, J&J has made several moves in the dermatology space, particularly for candidates being developed for the treatment of atopic dermatitis. In May, the pharma giant announced its $850m cash buyout of immune-mediated disease-focused biotech Proteologix for its bispecific antibody assets PX128 and PX130, which are designed to treat patients with moderate to severe manifestations of the chronic skin condition.
